Skip to content

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514656-32-00
Acronym
VABOR-KIDS-01
Enrollment
44
Registered
2024-12-19
Start date
2025-01-23
Completion date
Unknown
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected or confirmed Gram negative infections

Brief summary

Individual PK parameters derived with updated popPK models: Area under the concentrationtime curve (AUC), maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), drug clearance (CL), half-life (t1/2), minimum plasma concentration (Cmin), and steady-state volume of distribution (Vss).

Detailed description

Adverse Events (AEs), serious AEs (SAEs), and AE of special interest (AESI), as well as changes in clinical laboratory values, and vital signs following VaboremⓇ administration versus baseline.

Interventions

Sponsors

Menarini Ricerche S.p.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Secondary

MeasureTime frame
Adverse Events (AEs), serious AEs (SAEs), and AE of special interest (AESI), as well as changes in clinical laboratory values, and vital signs following VaboremⓇ administration versus baseline.

Primary

MeasureTime frame
Individual PK parameters derived with updated popPK models: Area under the concentrationtime curve (AUC), maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), drug clearance (CL), half-life (t1/2), minimum plasma concentration (Cmin), and steady-state volume of distribution (Vss).

Countries

Czechia, France, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026